Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy

Elzoghby A.O.; Ferrone C.R.; Ferrone S.Nasr M.L.

首页> 外文期刊>Drug discovery today >Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy

【24h】

Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy

机译：

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

? 2022 Elsevier LtdPancreatic cancer (PC) is a highly aggressive malignant type of cancer. Although immunotherapy has been successfully used for treatment of many cancer types, many challenges limit its success in PC. Therefore, nanomedicines were engineered to enhance the responsiveness of PC cells to immune checkpoint inhibitors (ICIs). In this review, we highlight recent advances in engineering nanomedicines to overcome PC immune resistance. Nanomedicines were used to increase the immunogenicity of PC cells, inactivate stromal cancer-associated fibroblasts (CAFs), enhance the antigen-presenting capacity of dendritic cells (DCs), reverse the highly immunosuppressive nature of the tumor microenvironment (TME), and, hence, improve the infiltration of cytotoxic T lymphocytes (CTLs), resulting in efficient antitumor immune responses.

著录项

来源
《Drug discovery today》 |2023年第1期|103434-103434|共5页
作者
Elzoghby A.O.; Ferrone C.R.; Ferrone S.Nasr M.L.;
展开▼
作者单位

Division of Engineering in Medicine Department of Medicine Brigham and Women's Hospital Harvard;

Department of Surgery Massachusetts General Hospital Harvard Medical School;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类药学;
关键词
drug delivery; immune checkpoint inhibitors; immunotherapy; nanomedicine; pancreatic cancer; resistance;

相似文献

外文文献
中文文献

1. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer [J] . JoonbeomBae, LongchaoLiu, CaseyMooreEricHsuAnliZhangZhenhuaRenZhichenSunXueWangJiankunZhuJiaoShenJianQiaoYang-XinFu Nature cell biology . 2022,第12期

机译：IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer
2. Stimuli-Sheddable Nanomedicine Overcoming Pathophysiological Barriers for Potentiating Immunotherapy of Cancer [J] . Wang Jiaxin, Zhou Mengxue, Chen FangminLiu XiaoGao JinWang WeiqiWang HuiYu Haijun Journal of biomedical nanotechnology . 2021,第8期

机译：Stimuli-Sheddable Nanomedicine Overcoming Pathophysiological Barriers for Potentiating Immunotherapy of Cancer
3. Nanomedicine for overcoming therapeutic and diagnostic challenges associated with pancreatic cancer [J] . Iyengar Disha, Tatiparti Katyayani, Gavande Navnath S.Sau SamareshIyer Arun K. Drug discovery today . 2022,第6期

机译：Nanomedicine for overcoming therapeutic and diagnostic challenges associated with pancreatic cancer
4. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. [O] . Williams, Timothy K, Costantino, Christina L, Bildzukewicz, Nikolai A, 2010

机译：pp32 (aNp32a) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNas.

Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy

摘要

著录项

相似文献

相关主题

期刊订阅